Abbott introduces new antibody blood test to detect SARS-CoV-2
Abbott has launched a new lab-based serology blood test to detect the IgG antibody, thereby identifying the presence of the novel coronavirus (COVID-19) in people. The new SARS-CoV-2
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XAbbott has launched a new lab-based serology blood test to detect the IgG antibody, thereby identifying the presence of the novel coronavirus (COVID-19) in people. The new SARS-CoV-2
US-based medical technology firm GE Healthcare has introduced a new software solution Mural to support clinicians and health systems in treating COVID-19 patients. The company has integrated its
Sanofi and GSK have agreed to collaborate on developing an adjuvanted vaccine for COVID-19, leveraging advanced technology from both companies. Under the collaboration, Sanofi will contribute its S-protein
AstraZeneca will initiate a randomised clinical trial to evaluate the potential of Calquence (acalabrutinib) to treat the exaggerated immune response (cytokine storm) in COVID-19 patients. The clinical trial
Bausch Health has started a clinical trial program evaluating the investigational VIRAZOLE (Ribavirin) in combination with standard of care therapy to treat respiratory distress due to COVID-19. The
Hope Biosciences (Hope Bio), a biotechnology firm developing cell-based therapeutics, has secured the second FDA approval for a Phase 2 clinical trial of its allogeneic, adipose-derived mesenchymal stem
Biopharmaceutical New Technologies (BioNTech) and Pfizer have unveiled plans of their collaboration to advance candidates from BioNTech’s mRNA vaccine programme. The collaboration, which was previously announced in March
AstraZeneca and Merck have obtained the US Food and Drug Administration (FDA) approval for Koselugo (selumetinib) to treat a type of neurofibromatosis in paediatric patients. FDA has indicated
Pfizer has secured the US Food and Drug Administration (FDA) approval for BRAFTOVI (encorafenib) in combination with cetuximab to treat a type of colorectal cancer (CRC). The US
US-based clinical-stage vaccine company Novavax has identified a vaccine candidate for coronavirus, dubbed NVX-CoV2373, a stable, prefusion protein developed through the advanced nanoparticle technology. The biotechnology firm said